Advertisement

Future Treatment and Other New Biologics for Asthma

  • Hiroshi OhnishiEmail author
  • Akihito Yokoyama
Chapter
Part of the Respiratory Disease Series: Diagnostic Tools and Disease Managements book series (RDSDTDM)

Abstract

Various cytokines and their receptors implicated in asthma pathophysiology are new targets for future treatments for severe asthma. There are several asthma endotypes that are characterized by the presence of (1) immunoglobulin E (IgE)-mediated inflammation, (2) type 2 inflammation (T2)-high, and (3) T2-low. Endotype-based approaches are new therapeutic strategies for severe asthma. In some countries, monoclonal antibodies (mAbs) that block IgE or interleukin (IL)-5 signaling are being used to treat severe allergic asthma and severe eosinophilic asthma, respectively. Neutralizing mAbs that target the IL-4/IL-13 signaling pathway and thymic stromal lymphopoietin (TSLP) were investigated in several clinical trials involving patients with severe asthma. Drugs generated from these mAbs, such as dupilumab and tezepelumab, may be promising treatments for severe asthma patients. An antagonist of the chemoattractant receptor-homologous molecule on Th2 cells (CRTh2) is another promising drug for the treatment of asthma. Macrolides are also effective for reducing asthma exacerbation in patients with severe asthma. Together, these therapies hold promise for more effective management of asthma.

Keywords

Biologic Chemoattractant receptor-homologous molecule on Th2 cells (CRTh2) IL-4 IL-5 IL-13 Macrolide Severe asthma Thymic stromal lymphopoietin (TSLP) 

Abbreviations

ACQ

Asthma control questionnaire

ADCC

Antibody-dependent cell cytotoxicity

AQLQ

Asthma quality of life questionnaire

AZM

Azithromycin

CRTh2

Chemoattractant receptor-homologous molecule on Th2 cells

EGPA

Eosinophilic granulomatosis with polyangiitis

FDA

Food and Drug Administration

FeNO

Fraction of exhaled nitric oxide

FEV1

Forced expiratory volume in 1 second

ICS

Inhaled corticosteroids

IgE

Immunoglobulin E

IL

Interleukin

ILC2

Group 2 innate lymphoid cells

LABA

Long-acting β2 agonist

LAMA

Long-acting muscarinic antagonist

mAb

Monoclonal antibody

OCS

Oral corticosteroids

QOL

Quality of life

Th2

Type 2 helper T

TSLP

Thymic stromal lymphopoietin

References

  1. 1.
    Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016;279:192–204.CrossRefGoogle Scholar
  2. 2.
    Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.Google Scholar
  3. 3.
    Swedin L, Saarne T, Rehnberg M, et al. Patient stratification and the unmet need in asthma. Pharmacol Ther. 2017;169:13–34.CrossRefGoogle Scholar
  4. 4.
    Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9.CrossRefGoogle Scholar
  5. 5.
    Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207.CrossRefGoogle Scholar
  6. 6.
    Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97.CrossRefGoogle Scholar
  7. 7.
    Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.CrossRefGoogle Scholar
  8. 8.
    Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–56.CrossRefGoogle Scholar
  9. 9.
    Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–32.CrossRefGoogle Scholar
  10. 10.
    Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–66.CrossRefGoogle Scholar
  11. 11.
    Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58.CrossRefGoogle Scholar
  12. 12.
    FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–41.CrossRefGoogle Scholar
  13. 13.
    Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27.CrossRefGoogle Scholar
  14. 14.
    FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64.CrossRefGoogle Scholar
  15. 15.
    Ohta K, Adachi M, Tohda Y, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018;67(2):266–72.CrossRefGoogle Scholar
  16. 16.
    Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–56.CrossRefGoogle Scholar
  17. 17.
    Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4:781–96.CrossRefGoogle Scholar
  18. 18.
    Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692–701.CrossRefGoogle Scholar
  19. 19.
    Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44.CrossRefGoogle Scholar
  20. 20.
    Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–10.CrossRefGoogle Scholar
  21. 21.
    Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936–46.CrossRefGoogle Scholar
  22. 22.
    Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16:186–200.CrossRefGoogle Scholar
  23. 23.
    Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71:1335–44.CrossRefGoogle Scholar
  24. 24.
    Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype in asthma. Am J Respir Crit Care Med. 2017;196:1385–95.CrossRefGoogle Scholar
  25. 25.
    Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46.CrossRefGoogle Scholar
  26. 26.
    Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086–1096.e5.CrossRefGoogle Scholar
  27. 27.
    Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5:568–76.CrossRefGoogle Scholar
  28. 28.
    Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–30.CrossRefGoogle Scholar
  29. 29.
    McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75:38–50.CrossRefGoogle Scholar
  30. 30.
    Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4:699–707.CrossRefGoogle Scholar
  31. 31.
    Bateman ED, Guerreros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J. 2017;50:1700670.CrossRefGoogle Scholar
  32. 32.
    Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:659–68.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Hematology and Respiratory Medicine, Kochi Medical SchoolKochi UniversityNankokuJapan

Personalised recommendations